Bioretec Oy 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Alan Donze

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	1.7yrs

최근 관리 업데이트

Recent updates

CEO

Alan Donze (59 yo)

less than a year

테뉴어

Mr. Alan Donze is Chief Executive Officer of Bioretec Oy from May 20, 2024. Mr. Donze has held senior leadership positions for a number of other medical device and technology companies including Smith Neph...

리더십 팀

이름	위치	테뉴어	보상	소유권
Alan Donze	Chief Executive Officer	less than a year	데이터 없음	데이터 없음
Johanna Salko	Chief Financial Officer	3.8yrs	데이터 없음	데이터 없음
Esa Hallinen	Director of Operations	1.3yrs	데이터 없음	데이터 없음
Timo Lehtonen	Chief Technology Officer	less than a year	데이터 없음	데이터 없음
Rami Ojala	Sales & Marketing Director	2.8yrs	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: BRETEC 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Tomi Numminen	Chairman of the Board	8.5yrs	데이터 없음	데이터 없음
Kustaa Poutiainen	Director	1.5yrs	데이터 없음	데이터 없음
Sarah Van Hellenberg Hubar-Fisher	Director	3.6yrs	데이터 없음	데이터 없음
Michael Piccirillo	Director	6.8yrs	데이터 없음	데이터 없음
Paivi Malinen	Director	2.6yrs	데이터 없음	데이터 없음
Klaus Dresing	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Fan Liu	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Theddy Slongo	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jeffrey Wang	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Richard Assaker	Member of Scientific Advisory Board	1.7yrs	데이터 없음	데이터 없음
Stefan Rammelt	Member of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음
Verena Schreiber	Member of Scientific Advisory Board	1.3yrs	데이터 없음	데이터 없음

1.7yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: BRETEC 의 이사회는 경험(평균 재직 기간 1.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Bioretec Oy 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Bioretec Oy Shareholders' Nomination Board Appointed

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd Announces CEO Changes

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Recent updates

Bioretec Oy has filed a Follow-on Equity Offering in the amount of €5 million.

Bioretec Ltd. Updates Its Product Development Strategy by Accelerating the Product Development of RemeOs™? Spinal Interbody Cage

Bioretec Oy Shareholders' Nomination Board Appointed

Bioretec Ltd. Reports Successful Clinical Outcomes from U.S. Controlled Launch of RemeOs Trauma Screw

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd. Receives a Patent by the U.S. Patent Office for its RemeOs Magnesium Alloy Composition

Bioretec Has Been Granted FDA Breakthrough Device Designation Status for its RemeOs Spinal Interbody Cage

New minor risk - Share price stability

Bioretec's European Market Authorization for RemeOs Trauma Screw Proceeded to Expert Panel Evaluation

Bioretec Oy to Report Q2, 2024 Results on Aug 15, 2024

Bioretec Ltd Announces CEO Changes

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Bioretec Ltd Appoints Dr. Jeremy Dublon as Regulatory Advisor

Bioretec Ltd Submits Additional Information Requested by the FDA for US Registration of RemeOs Trauma Screws

Bioretec Oy to Report First Half, 2023 Results on Aug 11, 2023

No independent directors

Bioretec Ltd, Updates Estimate of U.S. registration of RemeOs™ Screws and Expects Approval in April 2023

Bioretec's Hybrid Composite Patent Has Been Approved in Europe

Bioretec Oy Announces ActivaPin Bioresorbable Implant Provides Good Alternative Treatment of Pediatric Elbow Injuries

Bioretec Ltd Announces Bioresorbable Activa IM-Nail™ Shows Convincing Results in Post-Market Clinical Follow Up Study for the Treatment of Children's Forearm Fractures

Bioretec Ltd Submits Market Authorization Request for Its Bioresorbable RemeOs™ Magnesium Screw in the U.S

No independent directors

Bioretec's ActivaPin(TM) Bioresorbable Implant Provides Excellent Clinical Outcome in the Treatment of Pediatric Wrist Fractures

Bioretec Oy Announces Appointment of Päivi Malinen as Member of the Board of Directors

Bioretec Oy has completed an IPO in the amount of €1.74 million.

No independent directors

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령